Laura L. Michel

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

Mario Hlevnjak, Markus Schulze, Shaymaa Elgaafary et al. · JCO Precision Oncology · 2021 · 45 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs

Anna S. Berghoff, Yunxiang Liao, Matthia A. Karreman et al. · Molecular Cancer Research · 2020 · 35 citations · Full text

Medicine, Cell Biology, Oncology +17

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

Andreas Schneeweiß, Laura L. Michel, Volker Möbus et al. · European Journal of Cancer · 2021 · 33 citations

Medicine, Oncology, Pharmacology +14

Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling

Roberto Würth, Elisa Donato, Laura L. Michel et al. · Nature Cancer · 2025 · 32 citations · Full text

Medicine, Cancer Biology, Oncology +17